• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Nektar Therapeutics (NQ: NKTR )

    1.390 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2
    Open 1.390
    Bid (Size) 1.320 (2)
    Ask (Size) 1.410 (1)
    Prev. Close 1.390
    Today's Range 1.390 - 1.390
    52wk Range 0.4127 - 1.928
    Shares Outstanding 183,801,441
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NKTR Stock Earnings: Nektar Therapeutics Meets EPS, Beats Revenue for Q1 2024
    NKTR stock results show that Nektar Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga

    Performance

    YTD
    +133.69%
    +133.69%
    1 Month
    +13.93%
    +13.93%
    3 Month
    -4.79%
    -4.79%
    6 Month
    +148.21%
    +148.21%
    1 Year
    +159.43%
    +159.43%

    More News

    Read More
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Sweet Nektar?
    Via Talk Markets
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Nektar Therapeutics Earnings Preview
    Via Benzinga
    Recap: Nektar Therapeutics Q3 Earnings
    Via Benzinga
    A Preview Of Nektar Therapeutics's Earnings
    Via Benzinga
    Expert Ratings for Nektar Therapeutics
    Via Benzinga
    Biotech's Lawsuit With Eli Lilly Might Catalyze Stock
    Via Talk Markets
    Topics Lawsuit
    Exposures Financial Legal
    Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Nektar Therapeutics: Q1 Earnings Insights
    Via Benzinga
    Earnings Scheduled For March 4, 2024
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    The One-Minute Market Report - Saturday, Aug. 12
    Via Talk Markets
    Topics ETFs
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Why Is Nektar Therapeutics Stock Surging Today?
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
    Via Benzinga
    Tempur Sealy International To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Wednesday
    Via Benzinga
    Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions
    Via Benzinga
    7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
    Via InvestorPlace
    Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.